|
A)
|
E-CMF vs E-T-CMF
|
1.26
|
0.85-1.88
|
0.25
|
1.67
|
1.03-1.72
|
0.038
|
| |
Nodal involvement (≥ 4 vs 0-3)
|
3.53
|
1.82-6.85
|
< 0.001
|
2.96
|
2.96
|
0.004
|
| |
Hormone receptor status (pos. vs neg.)
|
0.48
|
0.31-0.77
|
0.002
|
0.40
|
0.24-0.68
|
0.018
|
| |
Ki-67 (high vs low)
|
1.97
|
1.06-3.65
|
0.031
|
2.77
|
1.19-6.46
|
0.018
|
| |
HER2&TOP2A gene (both ampl. vs all other)
|
0.12
|
0.02-0.88
|
0.037
|
0.16
|
0.02-1.14
|
0.067
|
|
B)
|
E-CMF vs E-T-CMF
|
1.16
|
0.77-1.75
|
0.47
|
1.56
|
0.95-2.57
|
0.079
|
| |
Nodal involvement (≥ 4 vs 0-3)
|
2.67
|
1.44-4.93
|
0.002
|
2.07
|
1.05-4.09
|
0.035
|
| |
Hormone receptor status (pos. vs neg.)
|
0.57
|
0.36-0.91
|
0.018
|
0.48
|
0.28-0.83
|
0.008
|
| |
Ki67 (high vs low)
|
1.92
|
0.98-3.77
|
0.057
|
3.40
|
1.22-9.48
|
0.019
|
| |
HER2&TOP2A mRNA (high vs low)
|
2.30
|
1.39-3.81
|
0.001
|
2.48
|
1.41-4.36
|
0.002
|
|
C)
|
E-CMF vs E-T-CMF
|
1.18
|
0.80-1.74
|
0.39
|
1.62
|
1.02-2.57
|
0.042
|
| |
Nodal involvement (≥ 4 vs 0-3)
|
3.00
|
1.64-5.49
|
< 0.001
|
2.43
|
1.25-4.73
|
0.009
|
| |
Hormone receptor status (pos. vs neg.)
|
0.64
|
0.41-0.99
|
0.047
|
0.51
|
0.31-0.85
|
0.009
|
| |
Ki67 (high vs low)
|
1.68
|
0.93-3.05
|
0.086
|
2.27
|
1.03-5.00
|
0.041
|
| |
HER2&TopoIIa IHC (both pos. vs all other)
|
1.77
|
1.04-3.05
|
0.034
|
1.58
|
0.86-2.91
|
0.14
|
|
D)
|
E-CMF vs E-T-CMF
|
1.13
|
0.73-1.75
|
0.59
|
1.53
|
0.89-2.26
|
0.12
|
| |
Nodal involvement (≥ 4 vs 0-3)
|
3.62
|
1.78-7.34
|
< 0.001
|
2.87
|
1.29-6.40
|
0.010
|
| |
Hormone receptor status (pos. vs neg.)
|
0.51
|
0.31-0.84
|
0.009
|
0.45
|
0.25-0.81
|
0.008
|
| |
Ki67 (high vs low)
|
2.05
|
0.99-4.21
|
0.051
|
4.35
|
1.34-14.18
|
0.015
|
| |
HER2&TOP2A gene (both ampl. vs all other)
|
0.13
|
0.02-0.96
|
0.046
|
0.23
|
0.03-1.74
|
0.15
|
| |
HER2&TOP2A mRNA (high vs low)
|
2.41
|
1.31-4.42
|
0.005
|
2.83
|
1.42-5.63
|
0.003
|
| |
HER2&TopoIIa IHC (both pos. vs all other)
|
1.36
|
0.68-2.70
|
0.38
|
0.92
|
0.42-2.18
|
0.92
|
